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Abstract
Neuropathic pain and pain that has a predominant neuropathic component can be difficult to
diagnose in primary care. Several screening questionnaires that incorporate patient symptoms and
signs have been developed, and some are supplemented with simple bedside clinical tests for nerve
dysfunction. These tools should enable a more rapid and confident diagnosis by the nonspecialist and
the earlier start of appropriate treatment.
Introduction and context
Neuropathic pain is defined by the International Associa-
tion for the Study of Pain (IASP) as ‘pain initiated or
caused by a primary lesion or dysfunction in the nervous
system’ [1]. There are many different causes of nerve
damage, and the presence or severity of pathology does
not correlate with the presence of pain [1]. Neuropathic
pain can be difficult to diagnose and is often missed in
primary care [2]. Also, there is a growing consensus that a
significant number of common pains consist of a mixture
ofneuropathic and nociceptive pain [3].There is a needto
improve the diagnosis and to document changes over
time more easily to allow assessment of natural progres-
sion or response to interventions. Clinical tests or the
completion of questionnaires (or a combination) are the
key tools. The Neuropathic Pain Special Interest Group,
known as NeuP SIG, has proposed that the IASP
definition be replaced by the following wording: ‘pain
arising as a direct consequence of a lesion or disease
affecting the somatosensory system’ [4]. These two
changes reflect the concept that in neuropathic pain an
aberrant somatosensory processing that goes beyond the
normal plasticity of the undamaged nociceptive system
is inferred. This proposal allows neuropathic pain to be
separated into ‘definite’ and ‘probable’ and so adds
relative and objective support to making the diagnosis
(see Figure from [4] for a flow chart of the grading system
for neuropathic pain).
The clinical importance of making a rapid and correct
diagnosis of neuropathic pain is that appropriate and
timely treatment will be started earlier [5]. For example,
less time will be lost trying the drugs commonly used
for nociceptive pain, such as paracetamol, anti-
inflammatories, and step 2 opioids, which have not
been shown to be effective for neuropathic pain.
Recent advances
Examination-based approaches
The correlation of neurological disease pathology with
pain experience is generally poor. A more common
approach is to look at changes in function of the nervous
system. Detailed laboratory tests are too time-consuming
and expensive for routine clinical use [6].
Skin biopsy has several advantages over nerve biopsies
(cost, repeatability, and ability to look at smaller fibres)
[7], but this looks at pathology only. The same can be
said for magnetic resonance neurography, which can
identify small patches of inflammation in peripheral
nerves.
Nerve conduction studies and somatosensory evoked
potentials may confirm a neuropathy, but they measure
function in large myelinated fibres only [6]. Quantitative
sensory testing (QST) is a sophisticated neurophysiolo-
gic technique that tests for loss of function and signs of
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large and small nerve fibres [7]. However, this test is
dependent on the cooperation of the patient, so
ultimately it is semi-objective. Results may be affected
deliberately by the patient or because of his or her
tiredness or lack of understanding about the responses
that are being studied [8].
A standardised protocol for QST was recently proposed
by the German Research Network on Neuropathic Pain
[9] and includes 13 parameters of sensory testing
procedures to document the exact somatosensory
phenotype of neuropathic pain patients. They confirmed
that there were no significant differences between left
and right sides of the body, suggesting that this method
may be more sensitive than absolute reference data for
the detection of changes. They also discovered that QST
(thermal and mechanical) thresholds varied with age
and body location and that gender affects pain but not
QST detection thresholds. However, this is a specialised
and time-consuming investigation (30 minutes for each
side) that is not easily transferred to primary care.
Some of the more simple individual QST tests can be
used to demonstrate neurological dysfunction and to
augment questionnaire-based tools. In a small study,
measurement of mechanical allodynia with von Frey
hairs showed that pain threshold was inversely related to
the severity of pain [10]. We have demonstrated in
healthy volunteers that a simple device consisting of a
blunt needle attached to a pressure gauge demonstrated
close correlation with von Frey hairs for detecting the
threshold for pain due to application of a pressure
[pressure-pain threshold (PPT)]. If this tool were
validated in patients, it would be much easier and
quicker for nonspecialists to implement than von Frey
hairs [11]. Also, a handheld bedside test for cold
hypoaesthesia (NeuroQuick; Schweers, Meerbusch,
Germany) has been found to have a high specificity
but a low sensitivity to identify small-fibre dysfunction
[12]. It may be useful to develop this concept further,
especially if a standardised stimulus intensity is adopted.
Questionnaire-based approaches
Several scoring systems for pain in general exist, but there
are now a variety of screening tools available for neuro-
pathic pain. The recent advances are described below; the
firsttwocombinesimpleclinicaltestsofnervedysfunction
as a supplement to the questionnaire (Figure 1).
1. Leeds Assessment of Neuropathic Symptoms and Signs
The Leeds Assessment of Neuropathic Symptoms and
S i g n s( L A N S S )w a st h ef i r s tt o o lt ob ed e v e l o p e d
and contains five symptom items and two clinical
examination items. It has a sensitivity and a specificity
ranging from 82-91% and 80-94%, respectively, and has
recently been validated as a self-report tool (S-LANSS)
[13,14]. Both LANSS and S-LANSS have been validated
in a variety of pain clinic settings, but they still need to be
validated for use in a primary care setting. LANSS may
have sensitivity to detect response to treatment [3,13-15].
2. Douleur Neuropathique en 4 Questions
Douleur Neuropathique en 4 Questions (DN4) has
seven items related to symptoms and three related to
clinical examination. It is simple to use and has been
translated into numerous languages. A sensitivity of 83%
and a specificity of 90% have been reported, and the
seven sensory descriptors have been used as a self-report
tool with similar accuracy [13,14].
3. Neuropathic Pain Questionnaire
The Neuropathic Pain Questionnaire (NPQ) contains
12 items: 10 related to sensations or sensory responses
and two related to affect. It has a sensitivity of 66% and a
specificity of 74% [13]. The short form of the NPQ
maintained similar discriminative properties when used
with only three items (numbness, tingling, and pain
increase in response to touch). It has previously been
found to be a valuable tool in identifying neuropathic
pain [16]. However, some feel that it has unacceptably
low diagnostic accuracy (68.4% compared with clinical
diagnosis) with little improvement in the score, even
when a complex statistical analysis was applied [17].
4. painDETECT
This is a self-report questionnaire of seven weighted
sensory descriptive items and two items related to the
spatial and temporal characteristics. In a comparison
against clinical examination, it correctly classified 83% of
patients with neuropathic pain and had a sensitivity of
85% and a specificity of 80% [13]. Some believe that the
graded answers increase the usefulness compared with
the yes/no criteria in other questionnaires [18].
5. ID Pain
This uses five sensory descriptor items and one item
relating to the joints which identifies nociceptive pain.
The group that invented the scale feel that it is more of a
screening tool [13,19].
6. Neuropathic Pain Scale
The Neuropathic Pain Scale (NPS) was developed for
monitoring response to treatment and not for estab-
lishing the diagnosis [20]. NPS seems to discriminate
between neuropathic and non-neuropathic pain, and
NPS scores have been shown to correlate well with
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have found it to be useful in discriminating between
neuropathic and non-neuropathic pain [16]. It is,
however, the only tool currently validated for central
neuropathic pain [21] and has proven to be a valid
and reliable tool for neuropathic pain in multiple
sclerosis [22].
7. Brief Pain Inventory
The Brief Pain Inventory (BPI) measures the severity of
pain and its interference with daily function but is not
specifically for neuropathic pain. However, a modified
version of the BPI was found to be a valid and reliable
measure for the evaluation of painful diabetic peripheral
neuropathy [23].
Implications for clinical practice
Screening tools are not perfect and it would be wrong to
suggest that they can replace a good clinical history and
examination. However, the biggest benefit will be for
screening purposes to assist the nonspecialist in the
identification of neuropathic pain or pain that has a
predominantly neuropathic component. We prefer to
use the LANSS and DN4 as they both use semi-objective
simple bedside tests for abnormal neural function. The
combination of history and examination is advanta-
geous. The BPI is very simple as a generic tool to assess
the impact of pain. The NPS, the only validated tool for
monitoring response to treatment, would be superseded
if the LANSS was also found to be effective in this role.
The further development of these tools will help to
identify patients earlier and so enable appropriate
neuropathic analgesic therapy to be initiated as soon as
possible. Ideally, these tools will also monitor the
response of interventions, so that pain control can be
further optimised.
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Figure 1. Common features within five neuropathic pain screening tools
aFeatures that involve clinical examination. Features common to five neuropathic screening tools are shown in the central column, with pricking, tingling and
pins and needles, electric shocks and shooting, and hot and burning pain being used to assess pain in all of the five tools shown in the diagram. The LANSS and
the DN4 both include simple clinical tests of nerve dysfunction as a supplement to the questionnaire. DN4, Douleur Neuropathique en 4 Questions; LANSS,
Leeds Assessment of Neuropathic Symptoms and Signs; NPQ, Neuropathic Pain Questionnaire.
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